BioNTech SE
BioNTech SE (BNTX) Stock Competitors & Peer Comparison
See (BNTX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BNTX | $93.02 | +0.00% | 23.8B | -15.85 | -$5.94 | N/A |
| VRTX | $437.09 | +2.84% | 109.1B | 25.51 | $16.85 | N/A |
| REGN | $709.53 | +0.06% | 73.6B | 17.44 | $40.99 | +0.50% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $801.56 | +1.81% | 48.4B | 34.75 | $22.51 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $290.28 | -1.90% | 39.4B | 74.32 | $3.97 | N/A |
| RVMD | $143.41 | +0.63% | 30.1B | -19.95 | -$7.11 | N/A |
| UTHR | $571.26 | +0.37% | 24B | 20.88 | $27.06 | N/A |
| INSM | $106.15 | +1.10% | 21.9B | -17.59 | -$5.76 | N/A |
Stock Comparison
BNTX vs VRTX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, VRTX has a market cap of 109.1B. Regarding current trading prices, BNTX is priced at $93.02, while VRTX trades at $437.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas VRTX's P/E ratio is 25.51. In terms of profitability, BNTX's ROE is -0.07%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, BNTX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check VRTX's competition here
BNTX vs REGN Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, REGN has a market cap of 73.6B. Regarding current trading prices, BNTX is priced at $93.02, while REGN trades at $709.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas REGN's P/E ratio is 17.44. In terms of profitability, BNTX's ROE is -0.07%, compared to REGN's ROE of +0.14%. Regarding short-term risk, BNTX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check REGN's competition here
BNTX vs VRNA Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, BNTX is priced at $93.02, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas VRNA's P/E ratio is -102.80. In terms of profitability, BNTX's ROE is -0.07%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, BNTX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check VRNA's competition here
BNTX vs ARGX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ARGX has a market cap of 48.4B. Regarding current trading prices, BNTX is priced at $93.02, while ARGX trades at $801.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ARGX's P/E ratio is 34.75. In terms of profitability, BNTX's ROE is -0.07%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, BNTX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ARGX's competition here
BNTX vs SGEN Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BNTX is priced at $93.02, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BNTX's ROE is -0.07%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BNTX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check SGEN's competition here
BNTX vs ALNY Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ALNY has a market cap of 39.4B. Regarding current trading prices, BNTX is priced at $93.02, while ALNY trades at $290.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ALNY's P/E ratio is 74.32. In terms of profitability, BNTX's ROE is -0.07%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, BNTX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ALNY's competition here
BNTX vs RVMD Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, RVMD has a market cap of 30.1B. Regarding current trading prices, BNTX is priced at $93.02, while RVMD trades at $143.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas RVMD's P/E ratio is -19.95. In terms of profitability, BNTX's ROE is -0.07%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, BNTX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RVMD's competition here
BNTX vs UTHR Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, UTHR has a market cap of 24B. Regarding current trading prices, BNTX is priced at $93.02, while UTHR trades at $571.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas UTHR's P/E ratio is 20.88. In terms of profitability, BNTX's ROE is -0.07%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BNTX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check UTHR's competition here
BNTX vs INSM Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, INSM has a market cap of 21.9B. Regarding current trading prices, BNTX is priced at $93.02, while INSM trades at $106.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas INSM's P/E ratio is -17.59. In terms of profitability, BNTX's ROE is -0.07%, compared to INSM's ROE of -1.30%. Regarding short-term risk, BNTX is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check INSM's competition here
BNTX vs RPRX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, RPRX has a market cap of 21.8B. Regarding current trading prices, BNTX is priced at $93.02, while RPRX trades at $51.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas RPRX's P/E ratio is 26.73. In terms of profitability, BNTX's ROE is -0.07%, compared to RPRX's ROE of +0.11%. Regarding short-term risk, BNTX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RPRX's competition here
BNTX vs MRNA Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, MRNA has a market cap of 21.6B. Regarding current trading prices, BNTX is priced at $93.02, while MRNA trades at $54.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas MRNA's P/E ratio is -6.68. In terms of profitability, BNTX's ROE is -0.07%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, BNTX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check MRNA's competition here
BNTX vs ROIV Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ROIV has a market cap of 20.4B. Regarding current trading prices, BNTX is priced at $93.02, while ROIV trades at $29.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ROIV's P/E ratio is -24.41. In terms of profitability, BNTX's ROE is -0.07%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, BNTX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ROIV's competition here
BNTX vs BGNE Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, BNTX is priced at $93.02, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas BGNE's P/E ratio is -22.55. In terms of profitability, BNTX's ROE is -0.07%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, BNTX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check BGNE's competition here
BNTX vs INCY Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, INCY has a market cap of 19.7B. Regarding current trading prices, BNTX is priced at $93.02, while INCY trades at $100.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas INCY's P/E ratio is 13.88. In terms of profitability, BNTX's ROE is -0.07%, compared to INCY's ROE of +0.29%. Regarding short-term risk, BNTX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check INCY's competition here
BNTX vs DNA-WT Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BNTX is priced at $93.02, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BNTX's ROE is -0.07%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, BNTX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check DNA-WT's competition here
BNTX vs GMAB Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, GMAB has a market cap of 16.3B. Regarding current trading prices, BNTX is priced at $93.02, while GMAB trades at $26.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas GMAB's P/E ratio is 20.18. In terms of profitability, BNTX's ROE is -0.07%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, BNTX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check GMAB's competition here
BNTX vs ASND Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ASND has a market cap of 14.6B. Regarding current trading prices, BNTX is priced at $93.02, while ASND trades at $239.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ASND's P/E ratio is 26.88. In terms of profitability, BNTX's ROE is -0.07%, compared to ASND's ROE of +1.28%. Regarding short-term risk, BNTX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ASND's competition here
BNTX vs JAZZ Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, JAZZ has a market cap of 14.2B. Regarding current trading prices, BNTX is priced at $93.02, while JAZZ trades at $226.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas JAZZ's P/E ratio is 2052.64. In terms of profitability, BNTX's ROE is -0.07%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, BNTX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check JAZZ's competition here
BNTX vs SMMT Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, BNTX is priced at $93.02, while SMMT trades at $18.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas SMMT's P/E ratio is -11.37. In terms of profitability, BNTX's ROE is -0.07%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, BNTX is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check SMMT's competition here
BNTX vs BBIO Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, BBIO has a market cap of 13.1B. Regarding current trading prices, BNTX is priced at $93.02, while BBIO trades at $65.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas BBIO's P/E ratio is -18.02. In terms of profitability, BNTX's ROE is -0.07%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, BNTX is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check BBIO's competition here
BNTX vs KRTX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BNTX is priced at $93.02, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BNTX's ROE is -0.07%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BNTX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check KRTX's competition here
BNTX vs IONS Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, BNTX is priced at $93.02, while IONS trades at $76.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas IONS's P/E ratio is -37.67. In terms of profitability, BNTX's ROE is -0.07%, compared to IONS's ROE of -0.59%. Regarding short-term risk, BNTX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check IONS's competition here
BNTX vs EXEL Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, EXEL has a market cap of 12.1B. Regarding current trading prices, BNTX is priced at $93.02, while EXEL trades at $49.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas EXEL's P/E ratio is 15.95. In terms of profitability, BNTX's ROE is -0.07%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, BNTX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check EXEL's competition here
BNTX vs MDGL Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, BNTX is priced at $93.02, while MDGL trades at $500.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas MDGL's P/E ratio is -37.84. In terms of profitability, BNTX's ROE is -0.07%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, BNTX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MDGL's competition here
BNTX vs RNAM Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, BNTX is priced at $93.02, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas RNAM's P/E ratio is -17.39. In terms of profitability, BNTX's ROE is -0.07%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, BNTX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RNAM's competition here
BNTX vs AXSM Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, BNTX is priced at $93.02, while AXSM trades at $217.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas AXSM's P/E ratio is -58.28. In terms of profitability, BNTX's ROE is -0.07%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, BNTX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check AXSM's competition here
BNTX vs BMRN Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, BNTX is priced at $93.02, while BMRN trades at $52.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas BMRN's P/E ratio is 38.89. In terms of profitability, BNTX's ROE is -0.07%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, BNTX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check BMRN's competition here
BNTX vs ARWR Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ARWR has a market cap of 10.2B. Regarding current trading prices, BNTX is priced at $93.02, while ARWR trades at $77.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ARWR's P/E ratio is 45.43. In terms of profitability, BNTX's ROE is -0.07%, compared to ARWR's ROE of -0.56%. Regarding short-term risk, BNTX is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check ARWR's competition here
BNTX vs CYTK Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, BNTX is priced at $93.02, while CYTK trades at $75.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas CYTK's P/E ratio is -11.23. In terms of profitability, BNTX's ROE is -0.07%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, BNTX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CYTK's competition here
BNTX vs RXDX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BNTX is priced at $93.02, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BNTX's ROE is -0.07%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BNTX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RXDX's competition here
BNTX vs KRYS Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, KRYS has a market cap of 9B. Regarding current trading prices, BNTX is priced at $93.02, while KRYS trades at $309.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas KRYS's P/E ratio is 40.87. In terms of profitability, BNTX's ROE is -0.07%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, BNTX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check KRYS's competition here
BNTX vs IBRX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, IBRX has a market cap of 8.7B. Regarding current trading prices, BNTX is priced at $93.02, while IBRX trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas IBRX's P/E ratio is -21.27. In terms of profitability, BNTX's ROE is -0.07%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, BNTX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check IBRX's competition here
BNTX vs IMGN Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BNTX is priced at $93.02, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BNTX's ROE is -0.07%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, BNTX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check IMGN's competition here
BNTX vs BPMC Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, BNTX is priced at $93.02, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas BPMC's P/E ratio is -51.58. In terms of profitability, BNTX's ROE is -0.07%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, BNTX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check BPMC's competition here
BNTX vs CERE Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BNTX is priced at $93.02, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas CERE's P/E ratio is -16.47. In terms of profitability, BNTX's ROE is -0.07%, compared to CERE's ROE of -0.72%. Regarding short-term risk, BNTX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CERE's competition here
BNTX vs ABVX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, BNTX is priced at $93.02, while ABVX trades at $119.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ABVX's P/E ratio is -21.65. In terms of profitability, BNTX's ROE is -0.07%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, BNTX is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ABVX's competition here
BNTX vs NUVL Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, BNTX is priced at $93.02, while NUVL trades at $105.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas NUVL's P/E ratio is -17.37. In terms of profitability, BNTX's ROE is -0.07%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, BNTX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check NUVL's competition here
BNTX vs PCVX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, PCVX has a market cap of 7.7B. Regarding current trading prices, BNTX is priced at $93.02, while PCVX trades at $53.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas PCVX's P/E ratio is -7.69. In terms of profitability, BNTX's ROE is -0.07%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, BNTX is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check PCVX's competition here
BNTX vs HALO Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, HALO has a market cap of 7.6B. Regarding current trading prices, BNTX is priced at $93.02, while HALO trades at $64.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas HALO's P/E ratio is 25.05. In terms of profitability, BNTX's ROE is -0.07%, compared to HALO's ROE of +0.93%. Regarding short-term risk, BNTX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check HALO's competition here
BNTX vs TECH Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, TECH has a market cap of 7.6B. Regarding current trading prices, BNTX is priced at $93.02, while TECH trades at $48.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas TECH's P/E ratio is 69.10. In terms of profitability, BNTX's ROE is -0.07%, compared to TECH's ROE of +0.05%. Regarding short-term risk, BNTX is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check TECH's competition here
BNTX vs MTSR Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, BNTX is priced at $93.02, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas MTSR's P/E ratio is -23.58. In terms of profitability, BNTX's ROE is -0.07%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, BNTX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MTSR's competition here
BNTX vs KYMR Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, KYMR has a market cap of 7.1B. Regarding current trading prices, BNTX is priced at $93.02, while KYMR trades at $85.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas KYMR's P/E ratio is -24.04. In terms of profitability, BNTX's ROE is -0.07%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, BNTX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check KYMR's competition here
BNTX vs PRAX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, PRAX has a market cap of 7B. Regarding current trading prices, BNTX is priced at $93.02, while PRAX trades at $331.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas PRAX's P/E ratio is -24.61. In terms of profitability, BNTX's ROE is -0.07%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, BNTX is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check PRAX's competition here
BNTX vs MRUS Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, BNTX is priced at $93.02, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas MRUS's P/E ratio is -17.05. In terms of profitability, BNTX's ROE is -0.07%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, BNTX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MRUS's competition here
BNTX vs ACLX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, BNTX is priced at $93.02, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ACLX's P/E ratio is -28.27. In terms of profitability, BNTX's ROE is -0.07%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, BNTX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ACLX's competition here
BNTX vs RETA Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BNTX is priced at $93.02, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas RETA's P/E ratio is -66.29. In terms of profitability, BNTX's ROE is -0.07%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BNTX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RETA's competition here
BNTX vs TGTX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, TGTX has a market cap of 6.6B. Regarding current trading prices, BNTX is priced at $93.02, while TGTX trades at $42.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas TGTX's P/E ratio is 14.99. In terms of profitability, BNTX's ROE is -0.07%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, BNTX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check TGTX's competition here
BNTX vs RYTM Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, RYTM has a market cap of 6.5B. Regarding current trading prices, BNTX is priced at $93.02, while RYTM trades at $89.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas RYTM's P/E ratio is -30.09. In terms of profitability, BNTX's ROE is -0.07%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, BNTX is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check RYTM's competition here
BNTX vs PTGX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, PTGX has a market cap of 6.4B. Regarding current trading prices, BNTX is priced at $93.02, while PTGX trades at $102.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas PTGX's P/E ratio is -54.90. In terms of profitability, BNTX's ROE is -0.07%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, BNTX is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check PTGX's competition here
BNTX vs CELC Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, CELC has a market cap of 6.3B. Regarding current trading prices, BNTX is priced at $93.02, while CELC trades at $128.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas CELC's P/E ratio is -29.92. In terms of profitability, BNTX's ROE is -0.07%, compared to CELC's ROE of -2.03%. Regarding short-term risk, BNTX is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CELC's competition here
BNTX vs BLTE Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, BNTX is priced at $93.02, while BLTE trades at $152.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas BLTE's P/E ratio is -67.34. In terms of profitability, BNTX's ROE is -0.07%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, BNTX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check BLTE's competition here
BNTX vs PTCT Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, BNTX is priced at $93.02, while PTCT trades at $76.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas PTCT's P/E ratio is 8.59. In terms of profitability, BNTX's ROE is -0.07%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, BNTX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check PTCT's competition here
BNTX vs COGT Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, BNTX is priced at $93.02, while COGT trades at $34.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas COGT's P/E ratio is -16.01. In terms of profitability, BNTX's ROE is -0.07%, compared to COGT's ROE of -0.83%. Regarding short-term risk, BNTX is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check COGT's competition here
BNTX vs CNTA Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, BNTX is priced at $93.02, while CNTA trades at $39.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas CNTA's P/E ratio is -27.12. In terms of profitability, BNTX's ROE is -0.07%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, BNTX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CNTA's competition here
BNTX vs IMVT Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, IMVT has a market cap of 5.9B. Regarding current trading prices, BNTX is priced at $93.02, while IMVT trades at $29.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas IMVT's P/E ratio is -10.84. In terms of profitability, BNTX's ROE is -0.07%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, BNTX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check IMVT's competition here
BNTX vs CGON Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, BNTX is priced at $93.02, while CGON trades at $69.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas CGON's P/E ratio is -33.47. In terms of profitability, BNTX's ROE is -0.07%, compared to CGON's ROE of -0.23%. Regarding short-term risk, BNTX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CGON's competition here
BNTX vs ALKS Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ALKS has a market cap of 5.8B. Regarding current trading prices, BNTX is priced at $93.02, while ALKS trades at $35.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ALKS's P/E ratio is 38.88. In terms of profitability, BNTX's ROE is -0.07%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, BNTX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ALKS's competition here
BNTX vs CDTX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, BNTX is priced at $93.02, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas CDTX's P/E ratio is -19.77. In terms of profitability, BNTX's ROE is -0.07%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, BNTX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CDTX's competition here
BNTX vs CORT Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, CORT has a market cap of 5.6B. Regarding current trading prices, BNTX is priced at $93.02, while CORT trades at $52.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas CORT's P/E ratio is 149.37. In terms of profitability, BNTX's ROE is -0.07%, compared to CORT's ROE of +0.08%. Regarding short-term risk, BNTX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CORT's competition here
BNTX vs SRRK Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, BNTX is priced at $93.02, while SRRK trades at $48.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas SRRK's P/E ratio is -14.71. In terms of profitability, BNTX's ROE is -0.07%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, BNTX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check SRRK's competition here
BNTX vs ABCM Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BNTX is priced at $93.02, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BNTX's ROE is -0.07%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BNTX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ABCM's competition here
BNTX vs ISEE Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BNTX is priced at $93.02, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BNTX's ROE is -0.07%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BNTX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ISEE's competition here
BNTX vs MIRM Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, BNTX is priced at $93.02, while MIRM trades at $105.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas MIRM's P/E ratio is -7.88. In terms of profitability, BNTX's ROE is -0.07%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, BNTX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MIRM's competition here
BNTX vs CRSP Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, BNTX is priced at $93.02, while CRSP trades at $54.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas CRSP's P/E ratio is -8.89. In terms of profitability, BNTX's ROE is -0.07%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, BNTX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CRSP's competition here
BNTX vs APLS Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, BNTX is priced at $93.02, while APLS trades at $41.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas APLS's P/E ratio is 38.36. In terms of profitability, BNTX's ROE is -0.07%, compared to APLS's ROE of +0.40%. Regarding short-term risk, BNTX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check APLS's competition here
BNTX vs LEGN Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, LEGN has a market cap of 5.2B. Regarding current trading prices, BNTX is priced at $93.02, while LEGN trades at $26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas LEGN's P/E ratio is -17.36. In terms of profitability, BNTX's ROE is -0.07%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, BNTX is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check LEGN's competition here
BNTX vs FBIOX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, BNTX is priced at $93.02, while FBIOX trades at $25.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas FBIOX's P/E ratio is N/A. In terms of profitability, BNTX's ROE is -0.07%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, BNTX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check FBIOX's competition here
BNTX vs APGE Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, BNTX is priced at $93.02, while APGE trades at $85.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas APGE's P/E ratio is -19.68. In terms of profitability, BNTX's ROE is -0.07%, compared to APGE's ROE of -0.37%. Regarding short-term risk, BNTX is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check APGE's competition here
BNTX vs TERN Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, BNTX is priced at $93.02, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas TERN's P/E ratio is -51.41. In terms of profitability, BNTX's ROE is -0.07%, compared to TERN's ROE of -0.20%. Regarding short-term risk, BNTX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check TERN's competition here
BNTX vs CAI Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, CAI has a market cap of 4.6B. Regarding current trading prices, BNTX is priced at $93.02, while CAI trades at $16.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas CAI's P/E ratio is -5.02. In terms of profitability, BNTX's ROE is -0.07%, compared to CAI's ROE of +0.06%. Regarding short-term risk, BNTX is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CAI's competition here
BNTX vs FOLD Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, BNTX is priced at $93.02, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas FOLD's P/E ratio is -161.00. In terms of profitability, BNTX's ROE is -0.07%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, BNTX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check FOLD's competition here
BNTX vs SYRE Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, SYRE has a market cap of 4.5B. Regarding current trading prices, BNTX is priced at $93.02, while SYRE trades at $77.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas SYRE's P/E ratio is -35.40. In terms of profitability, BNTX's ROE is -0.07%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, BNTX is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check SYRE's competition here
BNTX vs NAMS Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, NAMS has a market cap of 4.5B. Regarding current trading prices, BNTX is priced at $93.02, while NAMS trades at $40.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas NAMS's P/E ratio is -21.76. In terms of profitability, BNTX's ROE is -0.07%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, BNTX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check NAMS's competition here
BNTX vs AKRO Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, BNTX is priced at $93.02, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas AKRO's P/E ratio is -14.57. In terms of profitability, BNTX's ROE is -0.07%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, BNTX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check AKRO's competition here
BNTX vs ALPN Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BNTX is priced at $93.02, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BNTX's ROE is -0.07%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, BNTX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ALPN's competition here
BNTX vs XENE Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, BNTX is priced at $93.02, while XENE trades at $56.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas XENE's P/E ratio is -12.94. In terms of profitability, BNTX's ROE is -0.07%, compared to XENE's ROE of -0.48%. Regarding short-term risk, BNTX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check XENE's competition here
BNTX vs LGND Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, LGND has a market cap of 4.4B. Regarding current trading prices, BNTX is priced at $93.02, while LGND trades at $221.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas LGND's P/E ratio is 36.12. In terms of profitability, BNTX's ROE is -0.07%, compared to LGND's ROE of +0.16%. Regarding short-term risk, BNTX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check LGND's competition here
BNTX vs MANE Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, BNTX is priced at $93.02, while MANE trades at $108.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas MANE's P/E ratio is -44.48. In terms of profitability, BNTX's ROE is -0.07%, compared to MANE's ROE of -0.76%. Regarding short-term risk, BNTX is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check MANE's competition here
BNTX vs KNSA Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, KNSA has a market cap of 4.3B. Regarding current trading prices, BNTX is priced at $93.02, while KNSA trades at $58.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas KNSA's P/E ratio is 61.68. In terms of profitability, BNTX's ROE is -0.07%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, BNTX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check KNSA's competition here
BNTX vs OPT Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BNTX is priced at $93.02, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas OPT's P/E ratio is -1.52. In terms of profitability, BNTX's ROE is -0.07%, compared to OPT's ROE of +0.88%. Regarding short-term risk, BNTX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check OPT's competition here
BNTX vs MRTX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BNTX is priced at $93.02, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BNTX's ROE is -0.07%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BNTX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MRTX's competition here
BNTX vs TVTX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, TVTX has a market cap of 4B. Regarding current trading prices, BNTX is priced at $93.02, while TVTX trades at $42.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas TVTX's P/E ratio is -85.20. In terms of profitability, BNTX's ROE is -0.07%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, BNTX is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check TVTX's competition here
BNTX vs CRNX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, BNTX is priced at $93.02, while CRNX trades at $36.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas CRNX's P/E ratio is -7.57. In terms of profitability, BNTX's ROE is -0.07%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, BNTX is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check CRNX's competition here
BNTX vs ACAD Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, BNTX is priced at $93.02, while ACAD trades at $22.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ACAD's P/E ratio is 10.14. In terms of profitability, BNTX's ROE is -0.07%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, BNTX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ACAD's competition here
BNTX vs CPRX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, BNTX is priced at $93.02, while CPRX trades at $31.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas CPRX's P/E ratio is 18.54. In terms of profitability, BNTX's ROE is -0.07%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, BNTX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CPRX's competition here
BNTX vs EWTX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, EWTX has a market cap of 3.8B. Regarding current trading prices, BNTX is priced at $93.02, while EWTX trades at $34.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas EWTX's P/E ratio is -21.28. In terms of profitability, BNTX's ROE is -0.07%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, BNTX and EWTX have similar daily volatility (4.31).Check EWTX's competition here
BNTX vs RYZB Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BNTX is priced at $93.02, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BNTX's ROE is -0.07%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BNTX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RYZB's competition here
BNTX vs LQDA Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, LQDA has a market cap of 3.7B. Regarding current trading prices, BNTX is priced at $93.02, while LQDA trades at $49.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas LQDA's P/E ratio is -52.98. In terms of profitability, BNTX's ROE is -0.07%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, BNTX is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check LQDA's competition here
BNTX vs CBAY Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BNTX is priced at $93.02, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BNTX's ROE is -0.07%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, BNTX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CBAY's competition here
BNTX vs VKTX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, BNTX is priced at $93.02, while VKTX trades at $31.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas VKTX's P/E ratio is -7.55. In terms of profitability, BNTX's ROE is -0.07%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, BNTX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check VKTX's competition here
BNTX vs TLX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, BNTX is priced at $93.02, while TLX trades at $10.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas TLX's P/E ratio is -534.00. In terms of profitability, BNTX's ROE is -0.07%, compared to TLX's ROE of -0.02%. Regarding short-term risk, BNTX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check TLX's competition here
BNTX vs SWTX Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, BNTX is priced at $93.02, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas SWTX's P/E ratio is -13.78. In terms of profitability, BNTX's ROE is -0.07%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, BNTX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check SWTX's competition here
BNTX vs DNTH Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, DNTH has a market cap of 3.3B. Regarding current trading prices, BNTX is priced at $93.02, while DNTH trades at $86.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas DNTH's P/E ratio is -20.63. In terms of profitability, BNTX's ROE is -0.07%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, BNTX is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check DNTH's competition here
BNTX vs BEAM Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, BEAM has a market cap of 3.3B. Regarding current trading prices, BNTX is priced at $93.02, while BEAM trades at $32.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas BEAM's P/E ratio is -65.96. In terms of profitability, BNTX's ROE is -0.07%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, BNTX is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check BEAM's competition here
BNTX vs VCYT Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, BNTX is priced at $93.02, while VCYT trades at $40.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas VCYT's P/E ratio is 37.44. In terms of profitability, BNTX's ROE is -0.07%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, BNTX is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check VCYT's competition here
BNTX vs NAMSW Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, NAMSW has a market cap of 3.2B. Regarding current trading prices, BNTX is priced at $93.02, while NAMSW trades at $29.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas NAMSW's P/E ratio is N/A. In terms of profitability, BNTX's ROE is -0.07%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, BNTX is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check NAMSW's competition here
BNTX vs ERAS Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ERAS has a market cap of 3.1B. Regarding current trading prices, BNTX is priced at $93.02, while ERAS trades at $10.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ERAS's P/E ratio is -23.00. In terms of profitability, BNTX's ROE is -0.07%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, BNTX is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ERAS's competition here
BNTX vs DNLI Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, BNTX is priced at $93.02, while DNLI trades at $19.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas DNLI's P/E ratio is -6.61. In terms of profitability, BNTX's ROE is -0.07%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, BNTX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check DNLI's competition here
BNTX vs ANAB Comparison May 2026
BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNTX stands at 23.8B. In comparison, ANAB has a market cap of 3B. Regarding current trading prices, BNTX is priced at $93.02, while ANAB trades at $67.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNTX currently has a P/E ratio of -15.85, whereas ANAB's P/E ratio is -150.72. In terms of profitability, BNTX's ROE is -0.07%, compared to ANAB's ROE of +18.14%. Regarding short-term risk, BNTX is less volatile compared to ANAB. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check ANAB's competition here